Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention

**Abstract**

**Objective:** Currently, there is still no effective strategy to diminish the infarct size (IS) in patients with ST-segment elevation myocardial infarction (STEMI). According to a previous animal study, nicorandil treatment is a promising pharmaceutical treatment to limit the infarct area. In this study, we aim to investigate the effects of continual nicorandil administration on the IS and the clinical outcomes in patients with STEMI who underwent primary percutaneous coronary intervention (pPCI).

**Methods:** One hundred seventeen patients with STEMI and undergoing pPCI were randomly divided into the sustained nicorandil group (5 mg, three times daily) or the control group (only single nicorandil before PCI). The primary endpoint was the IS, evaluated by single-photon emission computed tomography (SPECT) 3 months after pPCI.

**Results:** Eighty-five patients completed the IS assessment via SPECT, and 99 participants were available for follow-up after 6 months. Finally, there was a statistical difference in the IS between the nicorandil and control groups (13% [interquartile range (IQR), 8–17] versus 16% [IQR, 12–20.3], p=0.027). Additionally, we observed that maintained nicorandil administration significantly improved the left ventricular ejection fraction at 3 months and enhanced the activity tolerance (physical limitation and angina stability) at 6 months after PCI.

**Conclusion:** Sustained nicorandil treatment reduced the IS and improved the clinical outcomes compared to the single nicorandil administration for patients with STEMI undergoing the pPCI procedure. Continuous cardioprotective therapy may be more beneficial for patients with STEMI.

(Anatol J Cardiol 2019; 21: 163-71)

**Keywords:** nicorandil, ST-segment elevation myocardial infarction, infarct size, percutaneous coronary intervention, single-photon emission computed tomography

**Introduction**

Timely reperfusion therapy, especially via primary percutaneous coronary intervention (pPCI), plays a key role in the treatment of the ST-segment elevation myocardial infarction (STEMI), and it contributes to a marked decrease in the acute mortality of patients with STEMI (1). However, the ischemic/reperfusion injury following pPCI remains unsolved and results in a lower myocardial survival rate and a higher morbidity of heart failure (2, 3). Coronary microvascular obstruction (CMVO) and myocardial injury widely existed in patients with acute myocardial infarction (AMI) after the treatment with PCI, contributing to the final infarct size (IS) (3-6). The IS is the major determinant of the adverse cardiac remodeling associated with unfavorable prognosis. Disappointingly, a vast number of clinical studies had not yet identified a solid strategy to diminish IS (4, 6-8). Thus, it is necessary to explore novel therapeutics.

Nicorandil, a combined agent with an adenosine triphosphate-sensitive K (K<sub>ATP</sub>) channel agonist and nitrate preparation, could improve clinical outcomes for ischemic heart disease through relieving both microcirculation dysfunction and myo-
cardiac injury (9-11). Additionally, several experimental studies have observed that nicorandil could reduce myocardial IS by approximately 50% (12-14). However, it is still controversial whether nicorandil diminishes IS in patients with acute myocardial infarct (15). Indeed, nicorandil was mostly administered a short time before PCI or during the perioperative period in previous trials (15, 16). However, microvascular obstruction would still deteriorate continuously after pPCI, and myocardial stunning may require several days or weeks to recover (10, 17). Thus, we decided to assess the effects of continuous oral nicorandil administration on decreasing IS and improving the outcome for STEMI patients with pPCI.

Methods

Patients

This trial was a pilot study with a prospective, randomized, open-label, and controlled design. One hundred thirty-four patients with their first STEMI were recruited consecutively in the Cardiac Care Unit of Xijing Hospital from September 2016 to February 2017. Briefly, inclusion criteria were as follows: (a) age between 18 and 79 years; (b) first STEMI diagnosis and prepared for pPCI treatment; and (c) within 12 hours from the onset of symptoms to hospital admission. The diagnosis of STEMI was given according to chest pain lasting for more than 30 minutes, at least 1 mm ST-segment elevation in two contiguous leads, and an increase in cardiospecific biomarkers.

Exclusion criteria were as follows: (a) previous myocardial infarction or cardiomyopathy; (b) culprit lesion in the left main trunk with hemodynamic instability; (c) Killip class III or IV; (d) failure to open occlusion by pPCI or transferred to coronary artery bypass grafting; (e) glucose control with sulfonlurea (K\textsubscript{ATP} channel inhibitor); (f) severe liver, kidney, or lung diseases; (g) history of drug allergy; and (h) severe glaucoma.

After meeting the eligibility criteria, patients with STEMI were assigned to the nicorandil group or the control group according to a stochastic sequence generated via the computer. All patients were given 5 mg of oral nicorandil after the hospital admission. Then, the nicorandil group was given 5 mg nicorandil three times a day for 6 months following PCI. Other treatments were completed according to the standard guidelines for both groups.

Protocols

All patients enrolled were treated on the basis of the current guidelines and recommendations for the management of patients with STEMI. Nicorandil was administered as an adjuvant treatment.

Once emergency patients were diagnosed with STEMI, dual antiplatelet therapy was given with a loading dose of aspirin, ticlopidine, or clopidogrel. Prior to catheterization, all patients received intravenous heparin (70 IU/kg). The pPCI procedure was performed in a standardized manner. Patients with no-reflow (TIMI flow grade ≤2) were treated with tirofiban, intracoronary sodium nitroprusside or adenosine in the catheterization laboratory. Statins, beta-blockers, angiotensin-converting enzyme inhibitor (ACEI), and angiotensin receptor blocker (ARB) were given according to the patient condition.

Electrocardiography was performed before entering the catheterization laboratory. Blood samples were taken to measure the levels of cardiospecific enzymes or biomarkers, such as CK-MB and Troponin I (TnI), after admission and 24 hours after PCI. Resting ECG-gated single-photon emission computed tomography (SPECT) was performed at 3 months after PCI. As described previously (18), the SPECT image acquisition began 50–60 min after the technetium-99 m-sestamibi injection (740–900 MBq, weight adjusted). After processing and reconstructing, an image analysis was performed using an Entegra (GE Medical Systems) processing station. The area of the deficiency was quantified with a threshold of 50% of the peak uptake. The IS was expressed as a percentage of the left ventricle. Echocardiography (Philips Ultrasound, Washington, USA) was performed to assess the left ventricular ejection fraction (LVEF) at admission, 1, 3, and 6 months after PCI. As our previous methods (18), echocardiograms were measured by two experienced cardiac ultrasound technicians blinded to the groups. If a discrepancy between the readings of >5% was noted, a third observer participated, and a consensus was achieved. The interobserver variability analysis showed a good repeatability (LVEF, 1.2±4.1%) with the Bland–Altman test. The Seattle Angina Questionnaire (SAQ) was recorded at 6 months. SAQ was applied to measure specific health conditions and the quality of life in coronary artery disease, including physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception (18). Additionally, we also collected major cardiac adverse events (MACE), including all-cause death, myocardial reinfarction, severe heart failure, and unplanned rehospitalization from a cardiac cause. Those examinations were performed by experienced colleagues who were blinded.

The primary endpoint was the IS quantified as a percentage of LV wall, was evaluated by SPECT at 3 months. The secondary endpoints were LVEF and SAQ assessed at 6 months. Our study was approved by the Ethical Committee of Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China. The protocol has been registered at www.chictr.org.cn (Clinical Trials number, ChiCTR-IPC-16009477). All of the patients gave their written, informed consent.

Statistical analysis

This study was a superiority trial, and the primary purpose was to observe whether sustained oral nicorandil reduced myocardial IS. We defined the power of the statistical test (1−β) as 0.8, the significance level α as 0.05. As in the current literature, the standard deviation (SD) of IS was assessed by SPECT, rang-
ing from 4% to 18% (18-20). We supposed that the mean±SD of IS for the nicorandil group was 15%±10% and that the IS for the control group was 20%±10%. A sample size of 50 patients would be required in each group. Given the ratio of loss for follow-up or withdrawal was 10%, the population that we needed was no less than 110. Taking into consideration that some patients refused or were unsuited for SPECT, we recruited another 10 patients consecutively.

Statistical analysis was based on the principle of Intention to Treat. Continuous data with a normal distribution were expressed as the means and standardized deviations, compared by Student’s t-test. If normality tests failed, the data were described as medians and interquartile ranges (IQR) and assessed by the Mann–Whitney U test. Categorical parameters were presented as a proportion or number, compared with the chi-square test or Fisher’s exact test. To perform a subgroup analysis, we transformed the primary endpoint of IS, to binary data [defining greater than or equal the median of IS (14%) as larger area]. The risk ratio and 95% confidence intervals were estimated and analyzed by a logistic regression analysis. Statistical analysis was performed with the SPSS software package (SPSS, version 14.0, Chicago, IL, USA) and STATA (StataCorp LP, version 10, College Station, Texas, USA). All tests were two-sided, and p-value of <0.05 was considered to be statistically significant.

**Results**

Figure 1 shows the patient profiles in the study. Of the 134 patients who were diagnosed as STEMI, 17 were excluded for

---

**Figure 1.** Diagram of study flow

NC - nicorandil; SPECT - single-photon emission computed tomography; SAQ - Seattle Angina Questionnaire scores; STEMI - ST-segment elevation myocardial infarction; PCI - percutaneous coronary intervention
several reasons (Killip III–IV class, previous MI, renal failure, oral sulfonylureas), and 117 patients were eligible in our study. The baseline characteristics of the patients are presented in Table 1. Finally, 99 patients with a first STEMI diagnosis in both groups completed the follow-up at 6 months. No significant difference was observed with regard to LVEF, CK-MB, and TnI before pPCI and coronary angiography features, indicating that the cardiac injury level in both groups may be similar before reperfusion (Table 1).

The impact of nicorandil on IS was evaluated by SPECT 3 months after pPCI and expressed as a percentage of the left ventricle wall (Fig. 2 and Table 2). Actually, only 85 patients performed the SPECT scan and were suitable for an IS assessment. No statistically significant difference was observed for population characteristics. The population characteristics were similar in patients who received the SPECT examination (Table 1).

Table 1. Baseline characteristics, angiographic data, and treatments

|                  | Nicorandil group (n=60) | Control group (n=57) | P-value |
|------------------|--------------------------|----------------------|---------|
| Age (years)      | 58.4±9.99                | 55.8±10.56           | 0.176   |
| Gender (male)    | 54 (90%)                 | 47 (82.5%)           | 0.235   |
| BMI              | 26.0±2.72                | 25.1±2.52            | 0.060   |
| SBP (mm Hg)      | 126.3±21.56              | 129.0±23.05          | 0.522   |
| DBP (mm Hg)      | 77.4±13.17               | 78.9±12.81           | 0.540   |
| Killip class (I) | 46 (76.7%)               | 39 (68.4%)           | 0.317   |
| Diabetes mellitus| 12 (20.0%)               | 10 (17.5%)           | 0.734   |
| Hypertension     | 28 (46.7%)               | 22 (38.6%)           | 0.378   |
| Current smoking  | 35 (58.3%)               | 27 (47.4%)           | 0.235   |
| Blood glucose (mmol/L) | 6.5±1.55            | 6.6±2.04             | 0.761   |
| TC (mmol/L)      | 3.8±0.82                 | 3.6±0.72             | 0.187   |
| TG (mmol/L)      | 1.64±0.90                | 1.61±1.01            | 0.851   |
| HDL              | 1.03±0.25                | 1.07±0.30            | 0.438   |
| LDL              | 2.26±0.84                | 2.31±0.87            | 0.769   |
| TnI (ng/mL)      | 6.8 (2.17-24.76)         | 6.5 (1.21-27.72)     | 0.524   |
| CK-MB (ng/mL)    | 55.1 (4.0-156.7)         | 46.9 (4.4-150.1)     | 0.579   |
| LVEF (%)         | 49 (42-57.75)            | 50 (43.5-57)         | 0.851   |
| Symptom-balloon  | 6 (4-9)                  | 5 (3.5-8)            | 0.170   |
| time (hours)     | IRA                      | 0.483                |         |
| IRA              | 31 (51.7%)               | 28 (49.1%)           |         |
| LAD              | 10 (16.7%)               | 6 (10.5%)            |         |
| RCA              | 19 (31.7%)               | 23 (40.4%)           |         |
| Multivessel disease (%) | 26 (43.3%) | 21 (36.8%) | 0.474 |
| TIMI flow grade  | before PCI               | 0.329                |         |
| 0                | 41 (68.3%)               | 42 (73.3%)           |         |
| 1                | 10 (16.7%)               | 4 (7.0%)             |         |
| 2                | 4 (6.7%)                 | 7 (12.3%)            |         |
| 3                | 5 (8.3%)                 | 4 (7.0%)             |         |
| Patients with stents (%) | 56 (93.3%) | 50 (87.7%) | 0.298 |
| Number of stents | 1.32±0.62                | 1.26±0.75            | 0.637   |
| Stent diameter (mm) | 3.23±0.64            | 3.06±0.77            | 0.141   |
| Final TIMI flow grade 3 | 53 (88.3%) | 51 (89.5%) | 0.844 |
| Medications of perioptive period | Aspirin | 60 (100%) | 57 (100%) | - |
| Aspirin          | 60 (100%)                | 57 (100%)            | -       |
| Clopidogrel      | 26 (43.3%)               | 30 (52.6%)           | 0.171   |
| Ticagrelor       | 34 (56.7%)               | 27 (47.4%)           | 0.314   |

Table 1. Cont.

|                  | Nicorandil group (n=60) | Control group (n=57) | P-value |
|------------------|--------------------------|----------------------|---------|
| Statins          | 60 (100%)                | 57 (100%)            | -       |
| β-blockers       | 52 (86.7%)               | 46 (80.7%)           | 0.382   |
| ACEI or ARB      | 41 (68.3%)               | 32 (56.1%)           | 0.174   |

Data are median (interquartile range), number (%) or mean (SD), unless otherwise stated. ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker; BMI - body mass index; CK-MB - creatinine kinase MB isoenzyme; HDL - high-density lipoprotein; LDL - low-density lipoprotein; TC - total cholesterol; TG - triglyceride; TnI - Troponin I; LVEF - left ventricular ejection fraction; IRA - infarct related artery; LAD - left anterior descending coronary artery; LCX - left circumflex artery; RCA - right coronary artery; TIMI - thrombolysis in Myocardial Infarction Score; PCI - percutaneous coronary intervention

Figure 2. Effect of continual oral nicorandil administration on the infarct size assessed by single-photon emission computed tomography at 3 months after percutaneous coronary intervention. Lines represent median and interquartile range. Spots indicate individual data
Supplemental Table 1. Baseline characteristics of patients with STEMI with IS assessment

|                      | Nicorandil group (n=43) | Control group (n=42) | P-value |
|----------------------|--------------------------|----------------------|---------|
| Age (years)          | 58.2±9.84                | 56.7±10.68           | 0.504   |
| Gender (male)        | 41 (95.3%)               | 35 (83.3%)           | 0.148   |
| BMI                  | 26.3±2.60                | 25.3±2.38            | 0.064   |
| Killip class (I)     | 33 (76.7%)               | 28 (66.7%)           | 0.302   |
| Diabetes mellitus    | 6 (14%)                  | 6 (14.3%)            | 0.965   |
| Hypertension         | 21 (48.8%)               | 17 (40.5%)           | 0.438   |
| Current smoking      | 26 (60.5%)               | 22 (52.4%)           | 0.452   |
| Blood glucose (mmol/L)| 6.7±2.15                 | 7.3±2.88             | 0.291   |
| TC (mmol/L)          | 3.8±0.86                 | 4.0±0.88             | 0.570   |
| TG (mmol/L)          | 1.5±0.81                 | 1.7±1.33             | 0.496   |
| Tnl (ng/ml)          | 4.0 (1.93-20.85)         | 3.7 (1.2-27.8)       | 0.651   |
| CK-MB (ng/mL)        | 50.8 (4.0-159.5)         | 41 (3.3-150.6)       | 0.276   |
| LVEF (%)             | 49 (43-57)               | 48 (43.8-55.3)       | 0.937   |
| Symptom-balloon time (hours) | 5 (3-8)         | 5 (2.6-7.6)          | 0.381   |

Supplemental Table 1. Baseline characteristics of patients with STEMI with IS assessment

|                      | Nicorandil group (n=43) | Control group (n=42) | P-value |
|----------------------|--------------------------|----------------------|---------|
| 3 months             |                          |                      |         |
| Infarct size (LV area %)* | 13 (8.0-17.0)          | 16 (12.0-20.3)       | 0.027   |
| 24 h                 |                          |                      |         |
| Tnl (ng/mL)          | 14.5 (3.58-46.55)        | 23.4 (5.01-67.25)    | 0.042   |
| CK-MB (ng/mL)        | 75.1 (5.4-183.6)         | 80.6 (5.1-194.6)     | 0.325   |
| 1 month              |                          |                      |         |
| LVEF (%)             | 63 (47-58)               | 50 (46-57)           | 0.230   |
| LVFS (%)             | 27 (23-30)               | 25 (22-30)           | 0.352   |
| LVESV (mL)           | 108 (93-118)             | 111 (91-131)         | 0.505   |
| LVEDV (mL)           | 52 (41-61)               | 52 (45-72)           | 0.302   |
| 3 months             |                          |                      |         |
| LVEF (%)             | 55 (51-58)               | 52 (47-56)           | 0.059   |
| LVFS (%)             | 28 (25-30)               | 26 (23-30)           | 0.095   |
| LVESV (mL)           | 108 (93-118)             | 110 (92-125)         | 0.105   |
| LVEDV (mL)           | 48 (36-60)               | 53 (42-62)           | 0.043   |
| 6 months             |                          |                      |         |
| LVEF (%)             | 55 (51-60)               | 52 (48-59)           | 0.090   |
| LVFS (%)             | 29 (25-31)               | 26 (24-30)           | 0.101   |
| LVESV (mL)           | 105 (93-113)             | 109 (99-125)         | 0.125   |
| LVEDV (mL)           | 48 (36-53)               | 53 (45-61)           | 0.053   |
| SAQ                  |                          |                      |         |
| Physical limitation  | 73.3±14.07               | 67.4±13.21           | 0.034   |
| Angina stability     | 63.8±10.74               | 55.8±12.10           | 0.001   |
| Angina frequency     | 79.3±12.07               | 77.3±14.09           | 0.445   |
| Treatment satisfaction | 86.5±8.32               | 88.2±6.87           | 0.282   |
| Disease perception   | 70.1±6.79                | 71.3±6.65           | 0.369   |

*Primary endpoint

Tnl - troponin I; CK-MB - creatinine kinase MB isoenzyme; LVEF - left ventricular ejection fraction; LVEDV - left ventricular end-diastolic volume; LVESV - left ventricular end-systolic volume; SV - stroke volume; SAQ - Seattle Angina Questionnaire scores
Supplemental Table 2. The incidence of MACE at 6 months after acute myocardial infarction

| Characteristics        | Nicorandil group | Control group | P-value |
|------------------------|------------------|---------------|---------|
| n=55                   | n=50             |               |         |
| MACE                   | 10 (18.2%)       | 13 (26.0%)    | 0.333   |
| All-cause death        | 3 (5.5%)         | 1 (2.0%)      | 0.679   |
| Reinfarction           | 0                | 2 (4.0%)      | 0.434   |
| Severe heart failure   | 4 (7.3%)         | 5 (10.0%)     | 0.881   |
| Rehospitalization**    | 6 (9.1%)         | 8 (16.0%)     | 0.300   |

**Unplanned rehospitalization for cardiac cause.
MACE includes all-cause death, myocardial reinfarction, severe heart failure, and unplanned rehospitalization from a cardiac cause. There was no significant difference in the incidence of adverse cardiac events. MACE - the major adverse cardiac events.

Supplemental Figure 1. Effects of long-term nicorandil administration on cardiac function
Left ventricular ejection fraction (LVEF) assessed by echocardiography at admission to hospital, and 1, 3, and 6 months after PCI. Sustained oral nicorandil treatment led to a significant improvement in LVEF at 3 months. Additionally, there was still a tendency toward a higher LVEF at 6 months, although the difference between both groups was moderate. The columns and error bars represent the median and interquartile ranges.

Maintained nicorandil also improved the quality of life for STEMI patients (Table 2 and Supplemental Fig. 1). The follow-up data of SAQ 6 months post-pPCI indicated that continual nicorandil treatment ameliorated physical limitations (73.3±14.07 vs. 67.4±13.21, p=0.034) and angina stability (63.8±10.74 vs. 55.8±12.10 p=0.001). A subgroup analysis did not reveal any statistical heterogeneity with regard to age, body mass index, diabetes mellitus, current smoking status, symptom onset-balloon time, and left anterior descending coronary artery (Fig. 3). No significant difference in the incidence of adverse cardiac events was observed (Supplemental Table 2).

Supplemental Figure 2. Effects of nicorandil on the quality of life at 6 months after percutaneous coronary intervention
Seattle Angina Questionnaire scores (SAQ) evaluate five aspects: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. Continuous nicorandil treatment ameliorated physical limitations and angina stability at 6 months after primary percutaneous coronary intervention. The columns and error bars represent the means and standard deviation (SD).

Figure 3. Subgroup analyses of the primary endpoint
Risk ratio, with 95% confidence intervals is applied to reflect the effect of nicorandil, with transforming continuous infarct size into a large infarct size (≥ median, 14%) and small. BMI - body mass index; LAD - left anterior descending coronary artery

Discussion
This study shows that compared with a single oral nicorandil treatment, sustained administration of nicorandil reduced myo-
cardiac infarction area [13%, (8–17) vs. 16% (12–20.3), p=0.027] and elevated LVEF (55% vs. 52%, p=0.039) and LVESV (48 mL vs. 53 mL, p=0.043) at 3 months and quality of life [physical limitation (73.3±14.07 vs. 67.4±13.21, p=0.034) and angina stability (63.8±10.74 vs. 55.8±12.10, p=0.001)] at 6 months in STEMI patients undergoing primary PCI. The IS is closely associated with clinical outcomes (21). The main purpose of our trial is to investigate the cardioprotective effects of continual nicorandil treatment on IS reduction in patients with STEMI and Killip I–II.

As it has a unique structure, nicorandil has a variety of cardiovascular protective mechanisms through the K_ATP channel agonism and NO pathways. Nicorandil effectively improves the symptoms and outcomes of ischemic heart disease (11, 22). In addition to relaxing large coronary vessels via NO, nicorandil dilates the microvasculature to improve cardiac perfusion by activating K_ATP channels specifically. Nicorandil also protects myocytes through opening K_ATP channels located in the sarcolemma and mitochondrion under ischemia-reperfusion conditions (9). Moreover, nicorandil has other cardioprotective mechanisms, such as inhibiting apoptosis and regulating cardiac sympathetic nerve activity and mediating autophagy (23–25).

According to the mechanisms described above, nicorandil may have a promising effect that can lessen the IS for AMI patients. As expected, animal experiments demonstrated that nicorandil reduced the infarct area by 52%–54.9% via activating the K_ATP channel (12, 13). Nevertheless, whether nicorandil limited the IS of patients with STEMI was still controversial. The J-WIND study aimed to assess whether nicorandil reduced the IS in patients with STEMI. Unexpectedly, nicorandil could not decrease the IS assessed by creatine kinase compared to the placebo. Another small study performed by Yamada et al. (16) enrolled 55 patients with AMI undergoing pPCI and administered intracoronary nicorandil or nitrate for 4 days. Their data revealed that nicorandil reduced IS by 18.9% compared with nitrate. In our study, the results exhibited that sustained oral nicorandil administration had the effect of reducing IS for patients STEMI undergoing pPCI.

Presumably, several reasons may explain this inconsistency. The J-WIND study employed continuous monitoring of CK to estimate IS indirectly. Although some studies indicated CK and CK-MB were associated with IS (correlation coefficient, 0.55–0.73). These biomarkers could only be thought as predictors of IS but not instead IS itself (21, 26, 27). Because reperfusion attached a rapid washout of CK in the ischemic band, it may affect the IS estimate (27). Second, the dosage impacted its effect. Previous studies also suggested that nicorandil improved exercise tolerance, cardiac function, and myocardial injury for CAD patients in a dose-dependent fashion. J-WIND study investigators also inferred the dosage of nicorandil is insufficient. Similarly, the primary endpoint in our trial was below expectations and may also be associated with dosage. Additionally, the time of medication may also be significant for nicorandil. In the J-WIND study, patients received intravenous nicorandil for 1 day, and no difference was observed. In Yamada et al. (16) study, nicorandil was given continuously for 4 days with a positive result. We evaluated IS at 3 months with continual oral nicorandil, and the above results may also support this point. In fact, there still remained persistent microvascular obstruction even at 6–10 days after MI (28, 29). Meanwhile, the stunned myocardium may need several weeks to recover contractile function (17, 30). Therefore, our trial, and previous studies, indicated that continuously alleviating CMVO and protecting cardiomyocytes were beneficial for saving variable myocardium.

In the present study, it was observed that the TnI level, rather than CK-MB, was statistically lower in the continual nicorandil group compared to the control group. The biomarker level was not measured successively, and those data only suggest that TnI at 24 h after PCI may be more sensitive than CK-MB to predict IS. Furthermore, other researchers observed early the CK-MB level at 4–12 h after PCI was a good predictor for IS, which may also support this point (26, 31). Consistent with previous reports, our results also indicated that sustained nicorandil administration elevated LVEF and the quality of life (15, 32). However, we did not observe a significant difference in LVEF at 6 months for both groups. Partly because the recovery of cardiac function existed in both groups as time passed, more patients were required to survey the effect. Additionally, numerous studies have demonstrated that nicorandil decreased the occurrence of MACE (11, 33). In this study, continuous nicorandil did not clearly affect the incidence of MACE, partly due to an insufficient sample size.

**Study limitations**

Several limitations existed in this study. First, the SPECT was chosen to assess IS in our study. Indeed, delayed enhancement CMR has a better spatial resolution to detect small myocardial infarcts than single-photon emission computed tomography (34). Second, we assessed IS at 3 months according to the equivalent myocardial injury of baseline. We did not collect the data about the area at risk at acute phases. Thus, the myocardial salvage index was not observed. Third, a follow-up for 6 months and a small sample size were insufficient to assess the long-term clinical outcomes and further subgroup analysis. Fourth, we just administered a routine dosage in this pilot study. The difference on IS was modest with 30% primary endpoint missing that resulted in possible selection bias. So it was not enough to be a clinical directive. Nicorandil plays a variety of biological roles in a dose-dependent manner (35–37), suggesting it may also reduce IS this way. Thus, the extent to which IS can be reduced by adjusting nicorandil administration still needs to be studied. Considering the distinct pathophysiology in the acute phase, we could further investigate the cardiac protective effect of nicorandil with sequential therapy, giving a large dose in the first week and continual standard doses thereafter.

**Conclusion**

A single administration of nicorandil before PCI may be insufficient to exert its protective effects. Our results suggest that
sustained nicorandil administration has a more beneficial effects on reducing IS and improving clinical outcomes for patients with STEMI undergoing pPCI. Furthermore, continual pharmaceutical administration seems to be a promising strategy to reduce the necrosis area compared with short-term intervention after the onset that needs further validation.

**Funding:** This work was supported by the National Natural Science Foundation of China (No. 81770224, No. 81570318, No. 81570361, No. 81670204), and National Key Research and Development Plan (2018YFA0107400).

**Conflict of interest:** None declared.

**Peer-review:** Externally and internally peer-reviewed.

**Authorship contributions:** Concept – S.W., Z.Z., D.S.; Design – S.W.; Supervision – S.W., Z.Z., D.S.; Fundings – H.W., Z.Z., D.S.; Materials – S.W., Z.Z., D.S.; Data collection &/or processing – Y.D., X.F., L.L., Z.S., B.W., C.X., WM; Analysis &/or interpretation – S.W., Z.Z., D.S.; Literature search – S.W., Z.Z., D.S.; Writing – S.W., Z.Z., D.S.; Critical review – H.W.

**References**

1. Dai X, Kaul P, Smith SC Jr, Stouffer GA. Predictors, treatment, and outcomes of STEMI occurring in hospitalized patients. Nat Rev Cardiol 2016; 13: 148-54.
2. Ndrepepa G. Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coron Artery Dis 2015; 26: 341-55.
3. Crea F. Coronary microvascular obstruction--a puzzle with many pieces. N Engl J Med 2015; 372: 1464-5.
4. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2018; 37: 1024-33.
5. Hausenloy DJ, Yellon DM. Targeting Myocardial Reperfusion Injury -The Search Continues. N Engl J Med 2015; 373: 1073-5.
6. Ferreira R. The reduction of infarct size--forty years of research--second of two parts. Rev Port Cardiol 2010; 29: 1219-44.
7. Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. JACC Cardiovasc Interv 2013; 6: 1056-63.
8. Kyhl K, Vejlstrup N, Lønborg J, Treiman M, Ahtarovski KA, Helqvist S, et al. Predictors and prognostic value of left atrial remodelling after acute myocardial infarction. Open Heart 2015; 2: e000223.
9. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011; 71: 1105-19.
10. Hirohata A, Yamamoto K, Hirose E, Kobayashi Y, Takafuji H, Sano F, et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study. Eur J Intervention 2014; 9: 1050-6.
11. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75.
12. Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. Cardiovasc Res 1998; 32: 274-85.
13. Schalla S, Higgins CB, Saeed M. Long-term oral treatment with nicorandil prevents the progression of left ventricular hypertrophy and preserves viability. J Cardiovasc Pharmacol 2005; 45: 333-40.
14. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, et al. Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. Circ J 2002; 66: 411-5.
15. Kitakaze M, Asakura M, Kim J, Shintani Y, Asoanuma H, Hamasaki T, et al.; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-93.
16. Yamada K, Isobe S, Ishii H, Yokouchi K, Iwata H, Sawada K, et al. Impacts of nicorandil on infarct myocardium in comparison with nitrate: assessed by cardiac magnetic resonance imaging. Heart Vessels 2016; 31: 1430-7.
17. Chalkias A, Xanthos T. Pathophysiology and pathogenesis of post-resuscitation myocardial stunning. Heart Fail Rev 2012; 17: 117-28.
18. Sun D, Narsinh K, Wang H, Li C, Li W, Zhang Z, et al. Effect of autologous bone marrow mononuclear cells transplantation in diabetic patients with ST-segment elevation myocardial infarction. Int J Cardiol 2013; 167: 537-47.
19. Sciagrá R, Cipollini F, Berti V, Migliorini A, Antonucci D, Pupi A.Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging 2013; 40: 542-7.
20. De Luca G, Parodi G, Sciagrá R, Bellandi B, Comito V, Vergara R, et al. Preinfarction angina does not affect infarct size in STEMI patients undergoing primary angioplasty. Atherosclerosis 2013; 226: 153-6.
21. Dohi T, Maehara A, Brener SJ, Généreux P, Gershlick AH, Mehran R, et al. Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial). Am J Cardiol 2015; 115: 563-70.
22. Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R; JCAD Investigators. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 2007; 71: 1835-40.
23. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007; 48: 1676-82.
24. Akao M, Teshima Y, Marbán E. Antiapoptotic effect of nicorandil mediated by mitochondrial ATP-sensitive potassium channels in cultured cardiac myocytes. J Am Coll Cardiol 2002; 40: 803-10.
25. Wang S, Fan Y, Feng X, Sun C, Shi Z, Li T, et al. Nicorandil alleviates myocardial injury and post-infarction cardiac remodeling by inhibiting Mst1. Biochem Biophys Res Commun 2018; 495: 292-9.
26. Rakowski T, Dziewierz A, Legutko J, Kleczynski P, Brzozowska-Klingensieck S, et al. Creatine kinase-MB assessed in patients undergoing primary angioplasty. Atherosclerosis 2013; 226: 153-6.
27. Di Chiara A, Plewka M, Werren M, Badano LP, Fresco C, Fioretti PM. Estimation of infarct size by single measurements of creatine kinase levels in patients with a first myocardial infarction. J Cardiovasc Med (Hagerstown) 2006; 7: 340-6.
28. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schultman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-72.

29. Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005; 26: 549-57.

30. Ambrosio G, Tritto I. Clinical manifestations of myocardial stunning. Coron Artery Dis 2001; 12: 357-61.

31. Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008; 1: 415-23.

32. Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009; 73: 925-31.

33. Sakata Y, Nakatani D, Shimizu M, Suna S, Usami M, Matsumoto S, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol 2012; 59: 14-21.

34. Lønborg J, Kelbaek H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012; 5: 288-95.

35. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol 1989; 63: 61J-65J.

36. Yang J, Zhang J, Cui W, Liu F, Xie R, Yang X, et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatol J Cardiol 2015; 15: 125-31.

37. Wu H, Ye M, Yang J, Ding J, Yang J, Dong W, et al. Nicorandil Protects the Heart from Ischemia/Reperfusion Injury by Attenuating Endoplasmic Reticulum Response-induced Apoptosis Through PI3K/Akt Signaling Pathway. Cell Physiol Biochem 2015; 35: 2320-32.